Multiple Myeloma Minimal Residual Disease (MRD) Testing
As more effective therapies have become available, the average overall survival length for newly diagnosed multiple myeloma patients has more than tripled since the early 2000s. In fact, the median overall survival is now greater than 10 years.¹ As a necessary step forward, strategies to detect minimal residual disease after completion of therapy have become increasingly important.
Why Should I Order MRD Testing?
Patients that do not achieve an MRD negative status will relapse faster and will have a shorter overall survival length.2
Assessing the level of MRD after completion of therapy provides physicians with valuable prognostic information and can help guide decisions for their continued treatment of these patients.
What Test Should I Order?
Multiple Myeloma Minimal Residual Disease by Flow, Bone Marrow (Mayo ID: MRDMM)
When Should I Order This Test?
Can This Test Be Used to Make Specific Therapy Decisions?
Currently, there isn’t prospective data to support therapy decisions like decreasing or stopping therapy in the setting of MRD negativity, or initiating treatment in the setting of MRD positivity. For high-risk patients who become MRD positive after being MRD negative, some physicians may choose to resume therapy. However, prospective data to prove the effectiveness has not yet been analyzed.
High-Sensitivity EuroFlow Testing to Meet Recommended Guidelines
With a sensitivity of 10-5
, our EuroFlow MRD test meets the guidelines recommended by the International Myeloma Working Group (IMWG),
National Comprehensive Cancer Network (NCCN), and the International Clinical Cytometry Society (ICCS).3
Additionally, because most clinical trials require the use of MRD testing with at least a 10-5 sensitivity, approaches that overcome the current limitations of conventional flow cytometry must be used.
1. Landgren O, Devlin S, Boulad M, et al: Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51(12): 1565-1568.
2. OncLive. The Role of MRD Testing in Myeloma. March 2, 2018. Accessed June 25, 2018. 2016;51(12): 1565-1568.
3. Kumar, S, Paiva B, Anderson, KC, et al: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology. 2016;17(8): e328-e346